Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SGO1 antisense RNA 1 (SGO1-AS1)
- Target
- SGO1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Non-coding RNA
01
Overview
SGO1 antisense RNA 1 (SGO1-AS1) is a long non-coding RNA (lncRNA), transcribed from the antisense strand partially overlapping the SGO1 (Shugoshin-like protein 1) gene. It does not encode a protein and is primarily localized in the cytoplasm. SGO1-AS1 is downregulated in several cancers, including gastric carcinoma and breast cancer, and acts as a tumor suppressor lncRNA. Mechanistically, it binds to the RNA-binding protein PTBP1, facilitating decay of TGFB1/2 mRNA, thereby reducing TGFβ signaling, which limits epithelial-to-mesenchymal transition (EMT), invasion, and metastasis. Its expression inversely correlates with cancer progression and metastasis, making it a candidate biomarker for prognosis in certain malignancies[1][2][5]. There are no known pharmacological agents directly targeting SGO1-AS1, nor established therapeutics that act through modulation of this lncRNA[1][2].
- Other names
- SGO1-AS1SGOL1-AS1SGOL1 antisense RNA 1 (non-protein coding)LOC101927829
02
Biological functions
Regulation of epithelial-to-mesenchymal transition (EMT)Negative regulation of TGFβ (transforming growth factor beta) signaling pathwayInhibition of cell invasion and metastasisModulation of mRNA stability (TGFB1/2 decay)
03
Disease associations
Cancer (notably gastric carcinoma and breast cancer)
04
Biomarkers
Downregulation of SGO1-AS1 associated with advanced stage, metastasis, and poor prognosis in gastric cancer[1]Transcript quantities informative for distinguishing breast cancer tissue from non-cancerous tissue[5]
Beyond the preview
Go deeper on SGO1 antisense RNA 1 (SGO1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SGO1 antisense RNA 1 (SGO1-AS1).